Highest-materiality recent filing
Advanced Biomed completes AI pivot with acquisition of Acellent Technologies
Acquired 100% of Acellent Technologies (HK) for 270,000 shares at $4/share, valued at $1.08M; closed April 30, 2026.
Advanced Biomed enters $600K unsecured loan at 10% interest, 6-month term
Loan of $600,000 from Jie Wang, unsecured, at 10% annual interest, maturing 6 months from disbursement.
Advanced Biomed agrees to acquire Acellent Technologies for 270K shares valued at $1.08M
Acquiring 100% of Acellent Technologies (Hong Kong), an AI-powered financial verification company.
Advanced Biomed CTO and director Steven I-Fang Cheng resigns; CFO Mingze Yin appointed to board
Steven I-Fang Cheng resigned as director and CTO effective March 25, 2026; no disagreement with company.
Advanced Biomed regains Nasdaq compliance after reverse stock split; stock remains listed
Received Panel decision on March 12, 2026 confirming compliance with Minimum Bid Price Rule.
Advanced Biomed announces 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse split effective Feb 20, 2026; every 20 shares become 1 share, par value unchanged $0.001.
Advanced Biomed issues 1.65M shares as commitment fee for $25M equity line
On Jan 30, 2026, issued 1,650,710 shares to HELENA GLOBAL for commitment fee under $25M equity line.
Advanced Biomed raises $248k via private placement of 4M shares at $0.062
Issued 4,000,000 shares of common stock at $0.062/share for total proceeds of $248,000.
Advanced Biomed enters supplemental agreement for $6.9M debt repayment from spun-off subsidiary
Advanced Biomed acknowledged $6,925,549 debt owed by Advanced Biomed (HK) Limited, its spun-off subsidiary.
Failed to regain minimum $1.00 bid price by Jan 14, 2026; Nasdaq notified delisting effective Jan 27, 2026.
Advanced Biomed sells Hong Kong subsidiary for $23K; moves clinical trials to Taiwan
Sold 100% of Advanced Biomed (HK) Limited and all IP of Shanghai Sglcell Biotech Co., Ltd. for US$23,000.
Advanced Biomed launches A+PerfusC 3D cell culture platform for precision medicine
A+PerfusC is a compact perfusion 3D cell culture incubator with automated perfusion and environmental control, mountable on a microscope for real-time observation.
Advanced Biomed receives Nasdaq bid price deficiency notice; has 180 days to regain compliance
Nasdaq notified ADVB on July 18, 2025, of bid price below $1.00 for 32 consecutive business days.
Advanced Biomed secures up to $25M equity purchase agreement with Helena Global
Company enters purchase agreement with HELENA GLOBAL for up to $25M of common stock.
Advanced Biomed board member Dr. Hung To Pau resigns, Steven I-Fang Cheng appointed
Dr. Hung To Pau resigned from the Board of Directors on May 23, 2025 for personal reasons.
On May 23, 2025, the Board of Directors of Advanced Biomed Inc. (the “Company”) accepted the resignation of Dr. Hung To Pau from the Board of Directors for personal reasons.
On May 23, 2025, the Board of Directors of the Company appointed Mr. Steven I-Fang Cheng as a member of the Board of Director, effective May 23, 2025.
Max materiality 0.90 · Median 0.60 · Most common event other_material